Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)

Medical Science Monitor

Volumn 17, Issue 4, 2011, Pages 189-195

  Wiggermann, Philipp ^a   Sieron, Dominik ^a,b   Brosche, Christiane ^a   Brauer, Thomas ^a   Scheer, Fabian ^a   Platzek, Ivan ^a   Wawrzynek, Wojciech ^b   Stroszczynski, Christian ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b District Hospital of Orthopaedics and Trauma Surgery   (Poland)

Author keywords

Cisplatin; Drug eluting bead; Epirubicin; HCC; TACE

Indexed keywords

CISPLATIN; EPIRUBICIN; IODINATED POPPYSEED OIL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG FEVER; FATIGUE; FEMALE; FEVER; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NAUSEA; SURVIVAL RATE; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE;

EID: 79953698419     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881714     Document Type: Article

References (25)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet, 2003; 362: 1907-17
2. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 2009; 27: 1485-91
3. Bolondi L, Sofia S, Siringo S et al: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 2001; 48: 251-59
4. Georgiades CS, Hong K, D'Angelo M, Geschwind JF: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol, 2005; 16: 1653-59
5. Geschwind JF: Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Interv Radiol, 2002; 13: 991-94
6. Witczak-Malinowska K, Zadrozny D, Studniarek M et al: Preliminary assessment of utility of radiofrequency ablation technique in treatment of primary hepatocellular carcinoma (HCC) in patients with hepatic cirrhosis. Med Sci Monit, 2003; 9(Suppl.3): 68-72
7. Mazzaferro V, Regalia E, Doci R et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996; 334: 693-99
8. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology, 2005; 42: 1208-36
9. Llovet JM, Real MI, Montana X et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002; 359: 1734-39
10. Lo CM, Ngan H, Tso WK et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002; 35: 1164-71
11. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003; 37: 429-42
12. Marelli L, Stigliano R, Triantos C et al: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol, 2007; 30: 6-25
13. Spahr L, Becker C, Pugin J et al: Acute portal hemodynamics and cytokine changesfollowing selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma. Med Sci Monit, 2003; 9(9): CR383-88
14. Lewis AL, Gonzalez MV, Leppard SW et al: Doxorubicin eluting beads-1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med, 2007; 18: 1691-99
15. Lewis AL, Gonzalez MV, Lloyd AW et al: DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol, 2006; 17: 335-42
16. D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2006; 44: 217-31
17. Xu J, Shi J, Wang YP et al: Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. Med Sci Monit, 2009; 15(6): CR274-79
18. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 1999; 19: 329-38
19. Sacks D, McClenny TE, Cardella JF, Lewis CA: Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol, 2003; 14: S199-202
20. Varela M, Real MI, Burrel M et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol, 2007; 46: 474-81
21. Poon RT, Tso WK, Pang RW et al: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drugeluting bead. Clin Gastroenterol Hepatol, 2007; 5: 1100-8
22. Hong K, Khwaja A, Liapi E et al: New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res, 2006; 12: 2563-67
23. Kettenbach J, Stadler A, Katzler IV et al: Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol, 2008; 31: 468-76
24. Malagari K, Chatzimichael K, Alexopoulou E et al: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol, 2008; 31: 269-80
25. Lammer J, Malagari K, Vogl T et al: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol, 2010; 33: 41-52